Evotec AG (NASDAQ:EVO) Short Interest Update

Key Points

• Short interest surged 80.2% to 91,437 shares as of August 31, up from 50,740 shares two weeks earlier. The short-interest ratio stood at 2.5 days, while reported short interest remained 0.0% of shares outstanding.
• Evotec shares closed flat at $1.63, near the 52-week low of $1.60 and below both the 50-day and 200-day moving averages. Trading volume was 24,906 shares versus an average of 91,663.
• Analyst sentiment was mixed but leaned toward caution, with a consensus “Hold” rating and a $3.00 target price; multiple firms recently downgraded the stock or lowered their price targets.

Evotec AG (NASDAQ:EVO - Get Free Report) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 91,437 shares, a growth of 80.2% from the August 15th total of 50,740 shares. Based on an average daily volume of 36,520 shares, the short-interest ratio is presently 2.5 days. Currently, 0.0% of the company's stock are short sold.

Evotec Stock Performance

NASDAQ EVO remained flat at $1.63 on Wednesday. 24,906 shares of the company's stock traded hands, compared to its average volume of 91,663. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The business has a 50 day simple moving average of $1.99 and a two-hundred day simple moving average of $2.53. Evotec has a 1 year low of $1.60 and a 1 year high of $4.27.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EVO. Berenberg Bank downgraded shares of Evotec from a "buy" rating to a "hold" rating in a research report on Thursday, July 16th. HC Wainwright reduced their price objective on shares of Evotec from $7.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, July 15th. TD Cowen downgraded Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. Finally, Weiss Ratings lowered Evotec from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $3.00.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently bought and sold shares of EVO. WCM Investment Management LLC raised its stake in Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company's stock valued at $1,480,000 after buying an additional 67,917 shares during the period. Optiver Holding B.V. increased its holdings in shares of Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company's stock worth $709,000 after acquiring an additional 242,973 shares during the last quarter. Fore Capital LLC acquired a new position in shares of Evotec during the 4th quarter worth approximately $97,000. SmartHarvest Portfolios LLC bought a new stake in Evotec in the 1st quarter valued at $44,000. Finally, Apollon Wealth Management LLC acquired a new stake in Evotec during the 1st quarter valued at $28,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic organizations. The company works across the research process, from early-stage target identification and assay development through hit identification, lead optimization, preclinical research and translational development.

Evotec uses technology platforms and scientific expertise in areas including small-molecule drug discovery, biologics, protein degradation, cell and gene therapy, and precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.